September 20-22 2022 | Boston, MA

www.nsclc-drug-development.com

BOOK BY JULY 8 TO SAVE UP TO $1,300

Non-Small Cell Lung Cancer Drug Development Summit

Transforming NSCLC Standards of Care with Next-Generation Therapies

Distilling Practice-Changing Therapeutic Sequencing, Combination & Trial Design, Overcoming Resistance & Promoting Effective Personalized Treatment of Actionable Mutations in NSCLC

Expert Speakers Include:

Stephen Liu
Associate Professor & Director, Head of Thoracic Oncology & Developmental Therapeutics
Georgetown University

Emmett Schmidt
Vice President, Lead External Collaborations Project Team Global Clinical Development
Merck & Co

Phillip Dennis
Vice President, Lung Cancer & Oncology Development
Sanofi

Anthony Jarkowski
Executive Director, Early Development & Program Lead
Bristol Myers Squibb

Jill Hallin
Senior Principal Scientist
Mirati Therapeutics

Sponsors natera biodesix

+1 617 455 4188 info@hansonwade.com
www.nsclc-drug-development.com

hansonwade

Welcome to the 2nd Non-Small Cell Lung Cancer Drug Development Summit

Advances in molecular and immunohistochemical techniques have ushered the NSCLC space into an exciting era of personalized medicine and improved outcomes – and a plethora of novel therapies are now in clinical development. Despite this, and whether patients fit into one of the actionable alteration subtypes of NSCLC or not, most will progress and/or develop resistance to currently available treatments.

The **2nd NSCLC Drug Development Summit** returns as the only industry-led forum for large bio-pharma, biotech and academic leaders to address mechanisms of drug resistance, spearhead progress in molecular subtyping and define practice-changing drug sequencing and combinations for the largest solid tumor indication.

This year's conference is focusing on:

- Refining molecular testing of NSCLC tumors and making next-generation sequencing tools more accessible in the clinical setting
- Investigating novel immune checkpoints and checkpoint inhibitor sequencing or combinations with surgery, chemo and/or radiotherapy where applicable, to define therapeutic options with better safety and efficacy outcomes in second-line or beyond
- Overcoming resistance mechanisms and patient progression after TKI treatment approaches for NSCLC tumors with actionable alterations
- Providing clarity on tumor biopsy testing guidelines to promote effective personalized treatment of patients
- Identifying truly transformative investigational drugs for use in the early vs. late-stage NSCLC setting and cut through the noise of increasingly complex therapeutic options
- Exploring trial design challenges to watch out for and tips for patient inclusion/exclusion criteria

With a huge unmet medical need for game-changing treatments that increase the length and quality of patient survival from diagnosis, there has never been a more important time to attend the **2nd NSCLC Drug Development Summit.** Join this dedicated and determined community to defeat NSCLC and radically change patients' lives.

5 Reasons Not to Miss Out:

Explore the realm of targeted therapies within NSCLC with clinical updates in an array of actionable mutations with **Mirati Therapeutics, Blueprint Medicines, Merus, Kinnate Biopharma & Verastem**

Understand developments in the IO space and how cutting-edge developers are overcoming challenges of patient selection with **Sanofi, Molecular Templates, Xcovery & Georgetown University**

Unlock the latest in the checkpoint space, with rationale and updates in combination strategy, addressing resistance and adjuvant/ neoadjuvant conversations with **Merck & Co, Bristol Myers Squibb & Immutep**

Delve into optimizing clinical trial design, moving your drug into earlier lines and various stages of the disease with **Iteron Therapeutics, Molecular Templates & LUNGevity Foundation**

Connect in person with your peers, ask your burning questions, get involved with workshops, build relationships with industry leaders and fully immerse yourself in the world of NSCLC drug development

+1 617 455 4188 info@hansonwade.com
www.nsclc-drug-development.com

hansonwade

Your Expert Speakers

Emmett Schmidt
Vice President, Lead External Collaborations Project Team Global Clinical Development
Merck & Co

Giovanni Selvaggi
Chief Executive Officer & Chief Medical Officer
Xcovery

Frederic Triebel
Chief Scientific Officer & Chief Medical Officer
Immutep

Cecile Geuijen
Chief Scientific Officer
Merus

Jill Feldman
Lung Cancer Patient and Advocate, Co-Founder
EGFR Resisters

Roger Waltzman
Chief Medical Officer
Molecular Templates

Eric Murphy
Chief Executive Officer, Chief Scientific Officer & Co-Founder
Alterome Therapeutics

Stephen Horrigan
Chief Scientific Officer
Iterion Therapeutics

Anthony Jarkowski
Executive Director, Early Development & Program Lead
Bristol Myers Squibb

Phillip Dennis
Vice President, Lung Cancer & Oncology Development
Sanofi

Jonathan Pachter
Chief Scientific Officer
Verastem

Stephen Liu
Associate Professor & Director, Head of Thoracic Oncology & Developmental Therapeutics
Georgetown University

Jill Hallin
Senior Principal Scientist
Mirati Therapeutics

Lauren Leiman
Executive Director
BloodPAC

Ryan Rountree
Senior Director, Preclinical Pharmacology
Nurix Therapeutics

Faris Albayya
Translational Medicine Scientist
Blueprint Medicines

Rob Kania
Senior Vice President of Drug Discovery
Kinnate

Elizabeth Barksdale
Director of Regulatory Affairs and Scientific Policy
LUNGevity Foundation

Blake Morrison
Vice President, Global Medical Affairs
Turning Point Therapeutics

Pre-Conference Workshops
Tuesday September 20, 2022

Workshop A — 9am-11am

Advancements in Disease Understanding & Early Detection of NSCLC

With many immunotherapies and targeted therapies redefining the NSCLC treatment landscape, a major hindrance to OS and PFS is that too often patients are diagnosed too late stage. Through disease understanding, technology and accessibility discussions, movements towards earlier detection are happening. This not only improves the clinical outcome for patients but increases the number of patients available for therapy and more selective trials, leading to more focused drug development efforts.

This workshop will cover:

- Understanding NSCLC disease pathology, 'high risk' and 'low risk' patients
- AI approaches/-omics for understanding NSCLC tumor heterogeneity and molecular signatures for patient stratification
- How AI ingestion of raw gene expression data from heterogenous patient samples are helping with novel NSCLC drug discovery and development
- How is this helping recruit patients that are most likely to respond to treatment? How are these approaches helping with toxicity mitigation?
- Discussions on accessibility, reimbursement and coverage policy

Workshop Leaders

Lauren Leiman
Executive Director
BloodPAC

Workshop B — 12pm-2pm

Preclinical NSCLC: Translating Your Therapy into the Clinic in a Competitive NSCLC Landscape

With an array of targeted & immuno therapies redefining the NSCLC treatment landscape, many are racing to get their drugs smartly, safely and efficaciously into the clinic. Understanding how the plethora of therapies for this vastly unmet disease will play out no matter what your modality is and learning how to differentiate your therapy from others is key.

This focused workshop will cover:

- Understanding the NSCLC treatment landscape and understanding where current therapies fit into the broader patient continuum of care
- Adding context to the approved standards of care – what are the benchmarks new therapies must overcome?
- Visualizing approvals on the horizon, sequence of therapies and line of care in the next 5-10 years
- Differentiating your approach and optimizing work preclinically
- Exploring relevant case studies

Workshop Leaders

Ryan Rountree
Senior Director, Preclinical Pharmacology
Nurix Therapeutics

Eric Murphy
Chief Executive Officer, Chief Scientific Officer & Co-Founder
Alterome Therapeutics

Conference Day One
Wednesday September 21, 2022

8.00 **Registration Opens**

Eric Murphy
Chief Executive Officer, Chief Scientific Officer & Co-Founder
Alterome Therapeutics

8.45 **Chair's Opening Remarks – Where Are We & Where Are We Going? Overview of Recent Exciting NSCLC Abstracts**

Emerging Approaches to Targeting NSCLC

Rob Kania
Senior Vice President of Drug Discovery
Kinnate

9.00 **Progress in Newly Diagnosed Actionable Mutations**
- Rationale & updates for novel TKIs
- Discussing the safety and efficacy of novel TKIs that target the eight molecular subtypes/currently actionable alterations
- Latest data & future directions

Jill Hallin
Senior Principal Scientist
Mirati Therapeutics

9.30 **KRAS G12C Development: New Opportunities...**
- Exploring adagrasib preclinical combinations
- Looking into patient combos, brain met data and more

Blake Morrison
Vice President, Global Medical Affairs
Turning Point Therapeutics

10.00 **Using Expanded Access Programs (EAPs) to Generate Meaningful Clinical and Real-World Evidence in Rare, Biomarker Driven NSCLC**
- Conventional clinical trials in rare, biomarker driven NSCLC patient populations are becoming increasingly challenging and competitive
- Utilizing Expanded Access Programs to generate additional clinical and real-world evidence is becoming increasingly important
- Balancing data collection with site personnel and patient burden for EAPs is key to achieving success

10.30 **Speed Networking**

11.00 **Morning Refreshments**

Drug Development Progress in Late-Line Non-Small Cell Lung Cancer

Roger Waltzman
Chief Medical Officer
Molecular Templates

12.00 **Investigating Safety & Efficacy of Novel Immunotherapies in Clinical Investigation in NSCLC**
- Understanding the translational timeline, patient population and combination rationale
- Exploring the latest clinical data, challenges and future directions into earlier lines

12.30 **Panel Discussion: Exploring the Strategic Challenges of Moving Forward a Drug You Want to Combine with PD-1 in Chemo+PD-1 Progressors**
- Understanding the different current comparators and benchmarks
- Exploring the differences in PD-1 naïve and PD-1 progressors
- Dissecting why sometimes beating chemo and PD-1 could be an unachievable bar
- Discussing whether with late-line in-effectivity, how you know it won't work in early line?
- Considering the health authorities' standards on the matter

Phillip Dennis
Vice President, Lung Cancer & Oncology Development
Sanofi

Stephen Horrigan
Chief Scientific Officer
Iterion Therapeutic

Emmett Schmidt
Vice President, Lead External Collaborations Project Team Global Clinical Development
Merck & Co

Roger Waltzman
Chief Medical Officer
Molecular Templates

Conference Day One
Wednesday September 21, 2022

1.00 **Lunch Break**

Understanding PD-1 Resistance & Improved Dissection of Patient Populations in Later-Line NSCLC

Faris Albayya
Translational Medicine Scientist
Blueprint Medicines

2.00 **Exploring BLU-945 in EGFR-Mutated NSCLC**
- Exploring the latest translational research
- Discussing potential combinations and treatment line
- Latest data and future directions

Roger Waltzman
Chief Medical Officer
Molecular Templates

2.30 **Exploring PD-L1 Targeting Through Multiple Mechanisms that May Overcome the Limitations of the PD-L1 Antibodies**

3.00 **Poster Session**

Optimizing Sequencing & Combination Rationale in Later Lines of Therapy

Speaker To Be Announced
Natera

3.30 **Informed By The Tumor: The Power of a Personalized ctDNA Assay For MRD Detection & Monitoring in NSCLC**
- Latest clinical data from 2022 publications and presentations
- Advantages of a personalized, tumor-informed ctDNA assay for molecular residual disease detection
- Applications of Signatera in clinical trial design to maximize trial success, and accelerate time to data readout

Phillip Dennis
Vice President, Lung Cancer & Oncology Development
Sanofi

4.00 **Advancements in ADCs for later-line NSCLC**
- Exploring the latest translational research
- Discussing potential combinations and treatment line
- Latest data and future directions

Emmett Schmidt
Vice President, Lead External Collaborations Project Team Global Clinical Development
Merck & Co

4.30 **Synergy is a 4 Letter Word: Lessons of Independent Action as an Explanation for the Efficacy of Cancer Clinical Combination Therapies**
- Immuno oncology drugs are failing at an unprecedented rate, perhaps because too much reliance has been placed on pre-clinical thinking about synergy
- Based on the mathematics of Independent Action, synergy has not been seen in any immuno oncology registration trials to date
- To progress development of combinations of ADC and PD-1 immune checkpoint inhibitors, the field must adapt more rigorous mathematic thinking about combination results

Giovanni Selvaggi
Chief Executive Officer & Chief Medical Officer
Xcovery

5.00 **Targeted Therapies in Late Lines of NSCLC: Sequencing & Combination Regimens**
- Relevance of sequencing drugs to address resistance
- Combination regimens to improve efficacy
- Addressing mechanisms of resistance to targeted therapies

5.30 **Chair's Closing Remarks & End of Day 1**

"A great meeting"

Scientific Director, Boehringer Ingelheim, Past Attendee

"Well organized and managed with global leaders in the NSCLC development space"

Chief Scientific Officer, Elevation Oncology, Previous Attendee

Conference Day Two
Thursday September 22, 2022

8.00 Coffee Room Opens

8.50 **Chair's Opening Remarks**

Progress in Mutation-Driven NSCLC Drug Development in Earlier Lines of Therapy

9.00 **Breakfast Panel: Bridging the TKI vs. Immunotherapy Conversations in NSCLC**

- Discussing stage of cancer, combinations, and order of treatment rationale for the well-validated immunotherapies and TKIs in early lines
- Exploring shifts of focus between the immune system of the patient (immunotherapies) and the biology of the tumor (tyrosine kinase inhibitors)
- How can we combine insights from both immune system markers and tumor markers, to be used as markers that are predictive of patient response?
- What are the rational targeted combinations for current TKIs?

Giovanni Selvaggi
Chief Executive Officer & Chief Medical Officer
Xcovery

Emmett Schmidt
Vice President, Lead External Collaborations Project Team Global Clinical Development
Merck & Co

Rob Kania
Senior Vice President of Drug Discovery
Kinnate

Jonathan Pachter
Chief Scientific Officer
Verastem

9.30 **The RAF/MEK Clamp VS-6766 for Treatment of KRAS & BRAF Mutant NSCLC**

- Exploring anti-tumor activity across multiple MAPK pathway alterations
- Ongoing VS-6766 combinations with FAK, KRAS G12C or mTOR inhibitors
- Revealing new combinations with EGFR inhibitors

Cecile Geuijen
Chief Scientific Officer
Merus

10.00 **The Bispecific Antibody MCLA-129 Impairs EGFR Inhibitor Resistant NSCLC Tumor Growth by Targeting EGFR & c-MET**

- Exploring the upregulation of c-MET signaling, which has been associated with resistance to EGFR inhibition
- Delving into MCLA-129: a bispecific antibody that blocks the signaling of EGFR as well as c-MET to inhibit tumor growth and survival
- Understand how MCLA-129 utilizes ADCC-enhancement technology, which increases its cell-killing potential by immune cells

10.30 Morning Refreshments

Stephen Horrigan
Chief Scientific Officer
Iterion Therapeutics

11.30 **Inhibition of the WNT/beta catenin Pathway in NSCLC**

- Understand the WNT/beta catenin pathway's importance as a target in NSCLC
- Explore the new therapeutics in development to inhibit this target
- Combination with EGFR inhibitors has potential to impact disease progression

Immune Checkpoint Inhibitors & Rational Combinations to Improve Outcomes in Earlier Lines of Therapy

Frederic Triebel
Chief Scientific Officer & Chief Medical Officer
Immutep

12.00 **A Soluble LAG-3 Protein (Eftilagimod Alpha) with an Anti-PD-1 Antibody (Pembrolizumab): Results of a Phase II Study in NSCLC**

- An MHC class II agonist (eftilagimod) used as an antigen presenting cell (APC) activator combined with an immune checkpoint inhibitor (ICI)
- Results in first (114 patients) and second (36 PD-X refractory patients) line NSCLC
- A systemic APC activator injected s.c. plus an ICI: a potent combination for PDL-1 unselected patients

Anthony Jarkowski
Executive Director, Early Development & Program Lead
Bristol Myers Squibb

12.30 **Exploring the Adjuvant vs. Neoadjuvant Debate**

- Understanding Nivolumab with chemotherapy as neoadjuvant treatment
- Discussing the data for adjuvant vs. neoadjuvant based on disease stage, actionable mutation status and PD-L1 status
- Delving into the thoughts and future directions of this dynamic conversation

Conference Day Two
Thursday September 22, 2022

1.00 **Lunch & Networking**

Optimizing Trial Design, Patient Recruitment & Patient Voice to Improve Trials

Speaker To Be Announced
Biodesix

2.00 **Utility of Blood-Based Molecular Diagnostic Testing Across the Lung Cancer Continuum of Care**

Stephen Liu
Associate Professor & Director, Head of Thoracic Oncology & Developmental Therapeutics
Georgetown University

2.30 **Overcoming Barriers to Clinical Trial Enrollment in NSCLC**

- Discussing thoughts on improving trial design, tailored towards clinical investigation during the pandemic
- Exploring telemedicine
- Overcoming barriers to trial enrollment
- Delving into smart trial design and optimizing study design in the midst of pandemic

3.00 **Physician Panel Discussion: Challenges & Practical Insights Into Optimizing Drug Sequencing & Patient Enrolment**

Stephen Liu
Associate Professor & Director, Head of Thoracic Oncology & Developmental Therapeutics
Georgetown University

Giovanni Selvaggi
Chief Executive Officer & Chief Medical Officer
Xcovery

- Discussing clinical trial design and patient inclusion/exclusion criteria when investigating drug sequencing
- Challenges in running the trials from a patient selection and management perspective (especially with all the different lines of therapy as inclusion/exclusion/selection criteria, meaning that many are not enrolled as they have been on a PD1 drug for a short time – how can pharma modify its inclusion criteria?)
- Exploring pain points and tips on patient enrolment for NSCLC clinical trials
- Analyzing sequencing: do you test the targeted therapy in a small biomarker select population or do you give that patient their first shot and the PD1, or do you put them together?
- What should come first: Immunotherapy when the patient has the strongest immune system or the small target agent?
- What is the role of chemotherapy in the above? And combining PD-1 with the TKI?
- After Pembro-chemo and/or Pembro-monotherapy in the PDL1 population, what do you do next?
- What is the progress in understanding the meaningful early biomarkers before you get to the 2-year endpoint?

3.30 **Afternoon Refreshments**

4.00 **Patient Advocacy Groups as Partners in Drug Development**

Elizabeth Barksdale
Director of Regulatory Affairs and Scientific Policy
LUNGevity Foundation

- PAGs like LUNGevity Foundation support patients with cancer in multiple ways, including by funding transformative research on disease biology, detection, and treatment
- LUNGevity has a demonstrated history of engaging stakeholders in the drug development ecosystem to address pain points and working together towards implementable solutions

4.15 **Centering the Patient in Our NSCLC Drug Development Journey**

Jill Feldman
Lung Cancer Patient and Advocate, Co-Founder
EGFR Resisters

- Discussing working with and informing patients, working with advocacy groups and more

4.30 **Chair's Closing Remarks & End of Summit**

Partnership Opportunities

We have entered a new era of NSCLC drug development that is impossible to ignore.

With the plethora of recent approvals of next-generation targeted and IO drugs, and the many more that are on the horizon, momentum is picking up and the world of possibilities for NSCLC patients is better than ever before. With this, the number of players in this field has skyrocketed and therefore so has the necessity for partners, collaborators and solution providers to support this expansion.

This is the only forum dedicated to NSCLC drug development, bringing together key leaders in this exciting space including large pharma, biotech, academia and technology providers. This unique, timely and exclusive meeting will not be one to miss.

If you provide services in tumor models, antibody manufacturing, clinical trials, diagnostics, biomarkers, or product development technology, this is your opportunity to put yourself in front of the key decision-makers in the field and present your expertise in solution services.

Whether you are looking to showcase exciting progress, generate leads or would like to understand the next-generation investment needs of the market, we can deliver the right solution for you.

Get in touch today to learn more about bespoke partnership opportunities.

Expertise Partner: Natera

Natera in cell-free DNA testing. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health. Natera operates an ISO13485- certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform.

www.natera.com

Expertise Partner: Biodesix

Biodesix® is an experienced partner in the field of blood-based molecular diagnostic testing. Our comprehensive diagnostic testing capabilities help our partners decipher the complexity of cancer by interpreting genomic and proteomic information from both tumor biology and the patient's immune response. Biodesix enables our partners throughout the discovery, development and commercialization of personalized diagnostics to support new therapies with companion diagnostic strategies.

www.biodesix.com

Company Type:



*Attendee breakdown from 1st NSCLC Drug Development Summit

Audience Seniority:



- 27% CXO
- 16% President/VP
- 16% Director
- 11% Head
- 10% Manager
- 20% Other

GET INVOLVED

Thomas Stockdale
Partnerships Director
Tel: : (+1) 6174554188
Email: sponsor@hansonwade.com

Ready to Register?

Non-Small Cell Lung Cancer Drug Development Summit
September 20-22 2022
Boston, MA

3 Easy Ways to Book

www.nsclc-drug-development.com/take-part/register

Tel: (+1) 617 455 4188

Email: register@hansonwade.com

1. **Join** your peers at the only congress dedicated to progressing NSCLC-centred drug development
2. **Delve** into the hottest topics from the last 12 months to revolutionize your work: from improving models to optimizing combinations and trial design
3. **Build connections** with potential collaborators, solution providers and pioneers in the industry

Secure Your Place Now

Drug Developer Pricing	Register & Pay By Friday, July 8	On the Door
Conference + 2 Workshops	$3,197	$4,297
Conference + 1 Workshop	$2,748	$3,648
Conference Only	$2,299	$2,999

Academic Pricing	Register & Pay By Friday, July 8	On the Door
Conference + 2 Workshops	$2,597	$3,697
Conference + 1 Workshop	$2,248	$3,148
Conference Only	$1,899	$2,599

Service Provider Pricing	Register & Pay By Friday, July 8	On the Door
Conference + 2 Workshops	$4,197	$5,497
Conference + 1 Workshop	$3,648	$4,748
Conference Only	$3,099	$3,999

All prices shown in USD. To qualify for the drug developer rate your company must have a public drug pipeline. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Team Discounts*

- **10% discount – 3 Attendees**
- **15% discount – 4 Attendees**
- **20% discount – 5+ Attendees**

Make the most of the **2nd NSCLC Drug Development Summit** Boston by attending with colleagues or registering your team. By attending as a group, you and your colleagues can make the most of the pre-conference workshops and networking sessions to ensure you leave with valuable connections and actionable insights.



VENUE

The Bostonian
26 North St, Boston, MA 02109, United States
https://www.millenniumhotels.com/en/boston/the-bostonian-boston/?cid=gplaces-the-bostonian-boston

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.tage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

+1 617 455 4188 info@hansonwade.com
www.nsclc-drug-development.com

hansonwade